Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Won’t Immediately Dispatch Investigators, ‘Guns Blazing,’ To Enforce UDI Regulation

This article was originally published in The Silver Sheet

Executive Summary

Details about how FDA will likely enforce its upcoming regulation on Unique Device Identification (UDI) are slowly emerging. Specifically, FDA will probably exercise enforcement discretion to give manufacturers and field investigators time to become accustomed to the new UDI requirements. Discretion action might “extend for the first three months or six months after the regulation goes into effect where FDA will not take aggressive enforcement actions,” former FDA official David Elder said. Ultimately, the agency says it will ensure manufacturer compliance to UDI by pursuing a risk-based approach. Meanwhile, FDA appears to have had a change of heart when it comes to prescribing a U.S.-based expiration date format for product labels.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel